Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab + XELOX followed by cetuximab + capecitabine maintenance in elderly patients with metastatic colorectal cancer
2006-007062-11Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin and capecitabine in metastatic colorectal adenocarcinoma (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Confirmed objective response rate. Started Jun 2007; status: completed.
02
Drugs
cetuximaboxaliplatincapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-007062-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007062-11.